RxDoctor Payments Data

Dawn Scott

Adult Health · Henderson, NYNPI 1699759100

Payments from drug & device makers

$522in general payments, 2019–2025

Across 29 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$106
  • Pfizer$87
  • AstraZeneca$87
  • Merck$69
  • Novo Nordisk$55
  • Abbott$37
  • plus $81 from 4 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$522 in reported general payments places this provider in the 55th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$17,989
Medicare patients
74
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol60$60,689
OzempicSemaglutide48$60,322
JanuviaSitagliptin Phosphate50$56,338
TrulicityDulaglutide27$39,923
XareltoRivaroxaban36$30,788
EliquisApixaban19$30,578
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$20,952
JardianceEmpagliflozin21$20,171
Breo ElliptaFluticasone/Vilanterol34$16,648
Xigduo XrDapaglifloz Propaned/Metformin11$11,779
Stiolto RespimatTiotropium Br/Olodaterol Hcl20$9,341
Incruse ElliptaUmeclidinium Bromide19$7,488
MyrbetriqMirabegron14$6,969
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$5,719
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$4,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$87$60,68960 claims
Novo NordiskOzempic$55$60,32248 claims
MerckJanuvia$69$56,33850 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$17$45,08769 claims
Lilly USA, LLCTrulicity$106$39,92327 claims
PfizerEliquis$87$30,57819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,828 adult health providers in New York.

Other adult health in Henderson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →